Key Points {#d30e179}
==========

Afatinib is an irreversible ErbB family blocker that potently inhibits signaling from all ErbB family receptor homodimers and heterodimers.In two large phase III trials, first-line afatinib significantly improved overall survival versus chemotherapy in non-small-cell lung cancer (NSCLC) patients specifically harboring epidermal growth factor receptor (*EGFR*) *Del19* mutations, as well as progression-free survival and patient-reported outcomes in patients with *EGFR* mutation-positive disease regardless of mutation type.Afatinib has demonstrated improved overall survival and progression-free survival versus erlotinib in patients with squamous cell carcinoma of the lung. It has also demonstrated promising activity in NSCLC patients with brain metastases, in patients who have failed prior chemotherapy and/or first-generation reversible EGFR tyrosine kinase inhibitors, and when continued in combination with paclitaxel beyond disease progression after monotherapy.

Introduction {#Sec1}
============

Over the last few decades, many advances have been made in the treatment of non-small-cell lung cancer (NSCLC), including improvements in cytotoxic chemotherapy regimens and the discovery of new targeted therapies \[[@CR1]\]. Despite these advances, NSCLC is still difficult to treat. Patients with NSCLC typically present with advanced disease, where localized therapy is not a viable option \[[@CR2]\]. Platinum-based chemotherapy, the standard first-line therapy for many patients, can prolong survival by 8--12 months in some cases and improve disease-related symptoms and quality of life (QoL) \[[@CR3]\]; however, outcomes are generally poor and tolerability is often a concern \[[@CR3]\]. For patients with refractory/relapsed disease, approved second-line treatments include docetaxel, pemetrexed, or erlotinib \[[@CR3]\], although survival benefits with these agents are modest \[[@CR4]--[@CR6]\]. The US FDA withdrew approval for gefitinib in this setting following the phase III ISEL (IRESSA^®^ Survival Evaluation in Lung Cancer) study that failed to demonstrate a significant overall survival (OS) benefit over placebo \[[@CR7]\]; however, subsequent studies have shown second-line gefitinib to be non-inferior to docetaxel, with improved tolerability \[[@CR8]\]. In part, the difficulty of treating NSCLC arises from the strikingly heterogeneous nature of the disease. In recent years, numerous oncogenic driver mutations have been identified in NSCLC, which has led to development of some molecularly targeted anticancer agents \[[@CR9]\]. To date, the following have been identified as druggable targets: rearrangements in the anaplastic lymphoma kinase (*ALK*) gene (3--5 % of patients) and mutations in the epidermal growth factor receptor (*EGFR*) \[[@CR2], [@CR9]--[@CR11]\].

EGFR is a member of a family of four structurally related receptor tyrosine kinases, the ErbB family kinases \[[@CR12], [@CR13]\]. In humans, this includes human epidermal growth factor 1 (HER1; EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). ErbB family proteins form homodimers, heterodimers, and possibly higher-order oligomers \[[@CR12], [@CR13]\]. The normal physiological role of the ErbB family is regulation of cellular proliferation \[[@CR12]\]. Dysregulated signaling through ErbB proteins has been associated with the development of a variety of cancers, including NSCLC \[[@CR12], [@CR13]\]. Many patients with NSCLC have somatic mutations of *EGFR* that lead to aberrant constitutive signaling via EGFR and its downstream networks; these abnormalities have been reported in about 50 % of Asian patients and 10--15 % of Caucasian patients with lung adenocarcinoma \[[@CR14]\]. Of the known *EGFR* mutations, the most common are exon 19 deletions (*Del19*) and an L858R point mutation (*L858R*) \[[@CR15]\]. Tumors with *EGFR*-activating mutations can become completely dependent on EGFR activity to stimulate downstream cell signaling networks ('oncogene addiction'). In this instance, blockade of EGFR with oral tyrosine kinase inhibitors (TKIs) blocks proliferation and initiates apoptosis \[[@CR16]\].

The first-generation reversible EGFR-TKIs, erlotinib and gefitinib, are approved first-line therapies for patients with NSCLC harboring activating *EGFR* mutations. In randomized phase III trials, both agents demonstrated improved progression-free survival (PFS) and response rates versus standard platinum-based chemotherapy in this setting (Table [1](#Tab1){ref-type="table"}) \[[@CR17]--[@CR23]\]. Unfortunately, however, virtually all patients who respond inevitably develop acquired resistance to these agents, and tumors rapidly regrow \[[@CR24]\]. Moreover, neither erlotinib nor gefitinib have demonstrated an OS benefit over chemotherapy \[[@CR17], [@CR25]--[@CR30]\]. Consequently, there has been intensive research into (1) mechanisms of resistance to first-generation inhibitors; (2) development of newer, more potent ErbB receptor family inhibitors that may offer (a) prolonged response in a first-line setting or (b) viable treatment options following the failure of first-generation inhibitors. In this review, we discuss the rationale for, and development of, second-generation TKIs with a focus on afatinib an irreversible, ErbB family blocker.Table 1Randomized phase III trials comparing epidermal growth factor receptor tyrosine kinase inhibitors to standard platinum-based chemotherapy for first-line treatment of advanced *EGFR* mutation-positive non-small-cell lung cancerTKIReferencesStudyGeographyComparatorPts (*n*)^a^RR (%)Median PFS^b^ (months)Difference in PFSMedian OS (months)Difference in OSDifference in OS-- Del19 mutationGefitinib\[[@CR20], [@CR25], [@CR28]\]IPASSEast AsiaCAR + PAC26171 vs. 479.5 vs. 6.3^c^0.48 (0.36--0.64); *p* \< 0.00121.6 vs. 21.91.00 (0.76--1.33); *p* = n.s0.79 (0.54--1.15)^d^; *p* = n.s\[[@CR17]\]^d^First-SIGNAL^d^South KoreaCIS + GEM4285 vs. 388.0 vs. 6.3^c^0.54 (0.27--1.1); *p* = n.s27.2 vs. 25.6^b^1.04 (0.50--2.18)^e^; *p* = n.sNA; *p* = n.s\[[@CR19], [@CR29]\]WJTOG 3405^f^JapanCIS + DOC17762 vs. 329.2 vs. 6.3^c^0.49 (0.34--0.71); *p* \< 0.000134.8 vs. 37.3^b^1.25 (0.88--1.78)^e^; *p* = n.sNA; *p* = n.s\[[@CR18], [@CR26], [@CR28]\]NEJGSG 002^d^JapanCAR + PAC23074 vs. 3110.8 vs. 5.4^g^0.30 (0.22--0.41); *p* \< 0.00127.7 vs. 26.60.89 (0.63--1.24); *p* = n.s0.83 (0.52--1.34)^e^; *p* = n.sErlotinib\[[@CR23], [@CR30]\]OPTIMALChinaCAR + GEM15483 vs. 3613.1 vs. 4.6^c^0.16 (0.10--0.26); *p* \< 0.000122.7 vs. 28.9^b^1.04 (0.69--1.58); *p* = n.sNA; *p* = n.s\[[@CR21]\]EURTACFrance, Italy, SpainCIS or CAR^h^ + DOC or GEM17358 vs. 159.7 vs. 5.2^g^0.37 (0.25--0.54); *p* \< 0.000119.3 vs. 19.5^b^1.04 (0.65--1.68); *p* = n.s0.94 (0.57--1.54)^e^; *p* = n.sAfatinib\[[@CR66], [@CR68]\]LL3GlobalCIS + PEM34556 vs. 2313.6 vs. 6.9^g^0.47 (0.34--0.65); *p* = 0.00131.6 vs. 28.2^b^0.78 (0.58--1.06); *p* = n.s0.54 (0.36--0.79); *p* = 0.0015\[[@CR67], [@CR68]\]LL6China, South Korea, ThailandCIS + GEM36467 vs. 2311.0 vs. 5.6^g^0.28 (0.20--0.39); *p* \< 0.000123.6 vs. 23.5^b^0.83 (0.62--1.09); *p* = n.s0.64 (0.44--0.94); *p* = 0.023Differences are presented as HR (95 % CI); *p* value*CAR* carboplatin, *CI* confidence interval, *CIS* cisplatin, *DOC* docetaxel, *EGFR* epidermal growth factor receptor, *GEM* gemcitabine, *HR* hazard ratio, *NA* not available, *n.s* not significant, *NSCLC* non-small-cell lung cancer, *OS* overall survival, *PAC* paclitaxel, *PEM* pemetrexed, *PFS* progression-free survival, *pts* patients, *RR* response rate, *TKI* tyrosine kinase inhibitor^a^Number of patients enrolled with *EGFR* mutations^b^In patients with common activating mutations (*Del19* and/or *L858R*)^c^Based on investigator assessment^d^Patients with *EGFR* mutations were a subgroup of all enrollees^e^No *p* value reported^f^Including patients with either post-operative recurrent or stage IIIb/IV NSCLC^g^Based on independent central review^h^CAR plus DOC or GEM was allowed for patients for whom CIS was contraindicated

First-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) {#Sec2}
=================================================================================================================================================

First-generation EGFR-TKIs bind reversibly to the kinase domain of the enzyme, inhibiting both mutated and, to a lesser extent, wild-type EGFR \[[@CR31]\]. They interrupt EGFR signaling through blockade of autophosphorylation, following competitive binding versus adenosine triphosphate (ATP) at the receptor intracellular catalytic domain \[[@CR32], [@CR33]\]. Initial phase III clinical trials of gefitinib versus chemotherapy (IPASS \[Iressa Pan-Asia study\] and First-SIGNAL \[First-line Single-agent Iressa versus Gemcitabine and cisplatin trial in Never-smokers with Adenocarcinoma of the Lung\]; Table [1](#Tab1){ref-type="table"}) \[[@CR17], [@CR20]\] were undertaken in patients who were not preselected based on *EGFR* mutation status; however, subgroup analyses and subsequent independent studies demonstrated that activating *EGFR* mutations were strongly predictive of improved outcomes with EGFR-TKIs \[[@CR17], [@CR20], [@CR34], [@CR35]\]. Consequently, additional phase III studies of gefitinib and erlotinib were conducted in preselected patients with activating *EGFR* mutations \[[@CR18], [@CR19], [@CR21], [@CR23]\], leading to regulatory approval of both agents (Table [1](#Tab1){ref-type="table"}).

In addition to the IPASS and First-SIGNAL trials conducted in Asian patients with advanced NSCLC, significant improvements in PFS with first-line gefitinib compared with platinum-doublet chemotherapy were reported in two phase III studies (NEJ002, WJTOG3405) in Japanese patients with *EGFR* mutation-positive NSCLC (Table [1](#Tab1){ref-type="table"}) \[[@CR18], [@CR19]\]. Currently, gefitinib is approved in Europe for the treatment of locally advanced or metastatic NSCLC with sensitizing *EGFR* mutations \[[@CR36]\]. In the USA, gefitinib is restricted to patients who, in the opinion of the treating physician, are currently benefitting from, or have previously benefitted from, treatment with this agent \[[@CR37]\].

In a phase III European trial (EURTAC \[European tarceva versus chemotherapy\]) comparing erlotinib with platinum-doublet chemotherapy in patients with advanced NSCLC and activating *EGFR* mutations, a significant improvement in median PFS (Table [1](#Tab1){ref-type="table"}) and better tolerability was observed with erlotinib versus chemotherapy \[[@CR21]\]. Similar findings for erlotinib were observed in a clinical trial (OPTIMAL) in Chinese patients \[[@CR23]\], and National Comprehensive Cancer Network (NCCN) guidelines were amended in 2011 on the strength of these data. In May 2013, erlotinib was approved by the US FDA for first-line treatment of patients whose tumors have common activating *EGFR* mutations \[[@CR38]\].

Erlotinib and gefitinib are also sometimes recommended as second- or third-line therapy in patients with NSCLC \[[@CR2]\]. In the case of erlotinib, this recommendation is independent of mutation status, based on a placebo-controlled, phase III trial in unselected relapsed/refractory NSCLC patients (BR21) \[[@CR6]\]. However, subsequent studies have indicated that the activity of erlotinib in second-/third-line settings is largely restricted to patients with activating *EGFR* mutations. In a phase III trial (TAILOR \[Tarceva Italian Lung Optimization tRial\]), erlotinib was compared with docetaxel as second-line therapy in patients with NSCLC and wild-type *EGFR*. In this study, PFS was significantly longer with docetaxel than with erlotinib in the overall study population and the subgroup of patients with adenocarcinoma histology; PFS was similar between treatment groups in the subgroup of patients with squamous histology \[[@CR39]\]. In another phase III trial (DELTA \[Docetaxel and Erlotinib Lung Cancer Trial\]), in an *EGFR*-unselected patient population, erlotinib failed to show an improvement in PFS or OS versus docetaxel in a second-/third-line setting \[[@CR40]\]. Taken together, these findings suggest that chemotherapy remains the most effective treatment option (albeit with modest activity) in the majority of *EGFR*-wild-type patients with relapsed/refractory NSCLC, although further studies with EGFR-TKIs in patients with squamous cell histology independent of *EGFR* mutation status are ongoing. However, despite the activity observed in the relapsed/refractory setting, chemotherapy, particularly docetaxel, is associated with poor tolerability \[[@CR39]\]. Therefore, there remains an unmet medical need for more effective and/or better tolerated second-line treatment options.

Resistance to First-Generation EGFR-TKIs {#Sec3}
========================================

Patients with NSCLC tumors harboring *EGFR* mutations inevitably develop resistance to first-generation EGFR-TKIs \[[@CR24]\]. The most common resistance mechanism defined to date (50--60 % of patients) is the accrual of a T790M missense mutation in exon 20 (*T790M*) \[[@CR41]--[@CR43]\]. This abnormality interferes with the binding of inhibitors of EGFR through steric hindrance \[[@CR44]\]. Other acquired resistance mechanisms are currently less well understood, although there is evidence that activation of other tyrosine kinase receptors, either due to overexpression or mutations, leads to compensatory signaling via proliferative pathways including the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) cascades \[[@CR45]\]. Receptors implicated in resistance to EGFR-TKIs include the MET receptor, a trans-membrane tyrosine kinase encoded by the proto-oncogene, *MET* and the insulin-like growth factor (IGF)-1 receptor \[[@CR46]--[@CR48]\]. Notably, other members of the ErbB family of receptors have also been implicated. Gene amplification or protein overexpression of HER2 can induce resistance to EGFR-TKIs \[[@CR49]\]. Furthermore, continuous exposure to first-generation inhibitors can confer overexpression of HER3 as a result of loss of AKT-mediated negative feedback signaling \[[@CR50]\]. Efforts to overcome these resistance mechanisms in NSCLC patients have included the development of irreversible ErbB family inhibitors that may provide more durable and prolonged responses in the first-line setting, as well as offering a potential treatment option in patients with acquired resistance to erlotinib/gefitinib. Other proposed, yet poorly understood, mechanisms of resistance include transformation to small-cell histology \[[@CR43]\] and epithelial to mesenchymal transition \[[@CR51]\].

Second-Generation TKIs: An Overview {#Sec4}
===================================

Based on the rationale above, several second-generation TKIs have been assessed in preclinical studies as well as in the clinic in patients with NSCLC. In brief, these include the following.

Dacomitinib {#Sec5}
-----------

Dacomitinib irreversibly inhibits EGFR, HER2, and HER4 and blocks signaling through all ErbB homodimers and heterodimers \[[@CR52], [@CR53]\]. In preclinical studies, dacomitinib was reported to inhibit EGFR signaling in tumors/cells harboring several different *EGFR* mutations, including *T790M* \[[@CR52]\]. Dacomitinib has been assessed in both first-line and relapsed/refractory settings in patients with NSCLC. In a recent phase II study, dacomitinib was reported to deliver a median PFS of 18.2 months in patients who had treatment-naïve NSCLC with activating *EGFR* mutations \[[@CR54]\]. A randomized phase III trial comparing dacomitinib and gefitinib in this setting is ongoing (ARCHER \[Advanced research for cancer targeted pan-HER therapy\] 1050). However, recent studies with dacomitinib in the relapsed/refractory setting have failed to achieve their primary objectives. In the phase III ARCHER 1009 study, which compared dacomitinib with erlotinib in patients with NSCLC who had previously received up to two chemotherapy regimens, median PFS was 2.6 months in both groups \[[@CR55]\]. In the phase III BR.26 trial, which assessed dacomitinib versus placebo in patients who had previously received chemotherapy and a first-generation reversible EGFR-TKI, there was no significant difference in OS between the two treatment arms, albeit PFS was significantly longer in patients who received dacomitinib (median 2.7 vs. 1.4 months; *p* \< 0.0001).

Neratinib {#Sec6}
---------

Neratinib is an irreversible inhibitor of EGFR and HER2. In preclinical studies, it was more effective than gefitinib at suppressing cell proliferation in lung cancer cell lines, including cells harboring the *T790M* mutation \[[@CR56]\]. Neratinib was assessed in a phase II study of patients with advanced NSCLC who had previously received at least 12 weeks of therapy with gefitinib or erlotinib. Response rates in this trial were very low; 3 % of patients with activating *EGFR* mutations and no patients with *T790M* achieved an objective response (OR) \[[@CR57]\]. A total of 50 % of patients developed grade 3 diarrhea at the previously determined maximum tolerated dose (MTD) of 320 mg/day \[[@CR58]\], and the phase II trial dose was subsequently reduced to 240 mg/day.

Afatinib {#Sec7}
--------

Afatinib covalently binds to EGFR, HER2, and ErbB4 \[[@CR59]\]. Such covalent binding irreversibly inhibits the tyrosine kinase activity of these receptors, resulting in reduced auto- and trans-phosphorylation within the ErbB dimers and inhibition of important steps in the signal transduction of all ErbB receptor family members (Fig. [1](#Fig1){ref-type="fig"}). The other ErbB family member, ErbB3, lacks intrinsic kinase activity but forms active heterodimers with other family members, particularly HER2 \[[@CR60]\]. Afatinib effectively silences signaling of all ErbB family heterodimers, including HER2/ErbB3 (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR59]\]. The irreversible inhibition of multiple ErbB family receptors by afatinib results in more potent and prolonged suppression of receptor kinase activity compared with reversible first-generation EGFR-TKIs \[[@CR31], [@CR59], [@CR61]\]. Afatinib is currently approved in the USA for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations as detected by an FDA-approved test \[[@CR62]\]. Afatinib is also approved for patients with NSCLC in over 40 countries worldwide, including the EU, Japan, Taiwan, and Canada. In the EU, it is indicated for patients with TKI-naïve NSCLC harboring activating *EGFR* mutations \[[@CR63]\]. The remainder of this review focuses on the preclinical and clinical development of afatinib in patients with NSCLC.Fig. 1Irreversible inhibition of ErbB receptor family signaling by afatinib. Covalent binding of afatinib to the ErbB family of receptors inhibits downstream signaling of all homodimers and heterodimers formed by these receptors \[[@CR59], [@CR61]\]. *AKT* protein kinase B, *EGFR* epidermal growth factor receptor, *ERK* extracellular signal-regulated kinase, *HER2* human epidermal growth factor receptor 2 (ErbB2), *MEK* mitogen-activated protein kinase kinase, *mTOR* mammalian target of rapamycin, *P13K* phosphoinositide 3-kinase, *RAF* rapidly accelerated fibrosarcoma, *RAS* rat sarcoma

Preclinical Development of Afatinib {#Sec8}
===================================

In cell-free in vitro kinase assays, afatinib demonstrated potent inhibition of wild-type EGFR, HER2, and ErbB4 at low nanomolar concentrations, whereas reversible TKIs erlotinib and gefitinib only inhibited EGFR (Table [2](#Tab2){ref-type="table"}) \[[@CR59]\]. Moreover, both cell-free assays and cell-based proliferation assays have shown that afatinib has potent inhibitory activity in the presence of the common EGFR-activating mutations, *L858R* and *Del19* \[[@CR59], [@CR61]\]. In contrast with erlotinib and gefitinib, afatinib was also active against NSCLC cells that overexpress HER2 (Table [2](#Tab2){ref-type="table"}).Table 2Inhibitory potency of afatinib, erlotinib, and gefitinib against ErbB family members in cell-free kinase assays and cell proliferation assays of various human lung cancer cell lines (nanomolar concentration causing 50 % inhibition (adapted from Solca et al. and Li et al. \[[@CR59], [@CR61]\])EGFR^WT^EGFR^L858R^EGFR^L858R/T790M^HER2HER4Cell-free kinase assays Afatinib0.2--0.70.2--0.49--107--250.7--1.7 Erlotinib0.9--1.71.1--2.71520--3562238--698579--756 Gefitinib0.4--4.70.8--1.4534--1267416--1830293--323Cell proliferation assays Afatinib600.792--22512--56NA Erlotinib11040\>4000\>4000NA Gefitinib1575\>4000\>4000NA*EGFR* epidermal growth factor receptor, *HER2* human epidermal growth factor receptor 2 (ErbB2), *WT* wild-type, *NA* not available

Afatinib inhibited cellular growth and induced apoptosis in several tumor cell lines, and resulted in tumor shrinkage in xenograft models of various cancer types, including NSCLC, pancreatic cancer, colorectal cancer, and head and neck squamous cell cancer \[[@CR64]\]. Afatinib also demonstrated activity in preclinical models of tumor cells resistant to reversible EGFR inhibitors, suggesting that irreversible ErbB family blockade could be effective in patients with reversible EGFR-TKI-resistant disease \[[@CR64], [@CR65]\]. Indeed, in cell-free kinase assays, afatinib inhibited EGFR harboring *L858R/T790M* at low nanomolar concentrations (half maximal effective concentration \[EC~50~\], 9--10 nM; Table [2](#Tab2){ref-type="table"}). Furthermore, afatinib inhibited cell growth in cultured lung cancer cells (EC~50~, 99 nM) and a lung cancer xenograft model harboring *L858R/T790M* \[[@CR61], [@CR64]\]. In comparison, EC~50~ values for erlotinib and gefitinib against *L858R/T790M* were \>500 nM in cell-free kinase assays (Table [2](#Tab2){ref-type="table"}) and \>4000 nM in cultured lung cancer cells \[[@CR61]\].

Taken together, the potent irreversible inhibition of signaling from all ErbB family receptor dimers formed by EGFR, HER2, and ErbB4, and preclinical antitumor activity observed in both EGFR-TKI-naïve and resistant cultured cells and xenograft models, provided biological rationale for the evaluation of afatinib in clinical trials.

Clinical Trials of First-Line Afatinib in Patients with NSCLC and Activating EGFR Mutations: LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) {#Sec9}
==================================================================================================================================

Trial Design {#Sec10}
------------

The LL3 (LUX-Lung 3; 345 patients recruited globally) and LL6 (364 patients recruited in China, South Korea, and Thailand) trials are the largest randomized, phase III trials ever to be undertaken in treatment-naïve patients with *EGFR* mutation-positive advanced NSCLC \[[@CR66]--[@CR68]\]. In contrast to the gefitinib and erlotinib registration studies, recruitment was not restricted to patients with tumors harboring *Del19* and/or *L858R*; the trial designs of LL3 and LL6 also incorporated patients with uncommon *EGFR* mutations (including *T790M*, exon 20 insertions, *G719X*, *S768I*, and *L861Q*, alone or as complex mutations in two or more exons). Patients were randomized (2:1) to afatinib (40 mg/day) or up to six cycles of standard-of-care platinum-based chemotherapy (cisplatin + pemetrexed \[LL3\] or cisplatin + gemcitabine \[LL6\]; selection based on the regulatory requirements of the different regions). It should be noted that cisplatin + pemetrexed was considered a state-of-the-art chemotherapy regimen when LL3 was designed and represented a more challenging comparator than used in other trials of EGFR-TKIs versus chemotherapy \[[@CR69]\].

The primary endpoint of LL3 and LL6 was PFS, by prespecified independent central review; the key secondary endpoint was OS. Both trials fully integrated comprehensive patient-reported outcomes (PROs) related to functional health status/QoL and lung cancer-related symptoms; these were evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire C30 (QLQ-C30) and its lung cancer-specific module (QLQ-LC13) (Table [3](#Tab3){ref-type="table"}) \[[@CR66], [@CR67], [@CR70]\].Table 3Patient-reported outcome assessments in first-line *EGFR* mutation-positive clinical trialsTrialTreatmentsQoL assessmentsMethodologyOutcomesIPASS \[[@CR20]\]Gefitinib vs. carboplatin + paclitaxelFACT-L and FACT-TOIRandomization, week 1, every 3 weeks until day 127, once every 6 weeks from day 128 until disease progression, and when the study drug was discontinuedSignificantly more pts in the gefitinib group than in the carboplatin + paclitaxel group had a clinically relevant improvement in QoL and by scores on the FACT-TOI. Rates of reduction in symptoms were similarEURTAC \[[@CR21]\]Erlotinib vs. cisplatin + docetaxel or gemcitabineCompletion of the lung cancer symptom scaleBaseline, every 3 weeks, end-of-treatment visit and every 3 months during follow-upInsufficient data collected for any analysis to be done, due to low complianceLL3 \[[@CR66], [@CR70]\]Afatinib vs. cisplatin + pemetrexedEORTC QLQ-C30, EORTC QLQ-LC13Baseline, every 3 weeks until disease progressionAfatinib improved lung cancer-related symptoms and QoL, and delay of deterioration of symptoms vs. chemotherapyLL6 \[[@CR67]\]Afatinib vs. gemcitabine + cisplatinEORTC QLQ-C30, EORTC QLQ-LC13Baseline, every 3 weeks until disease progressionAfatinib improved lung cancer-related symptoms of cough, dyspnea, and pain, and global health status/QoL vs. chemotherapy*EGFR* epidermal growth factor receptor, *EORTC*-*QLQ* European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, *FACT*-*L* Functional Assessment of Cancer Therapy -- Lung, *FACT*-*TOI* Functional Assessment of Cancer Therapy -- Trial Outcome Index, *QLQ*-*LC13* Quality of Life Questionnaire -- Lung Cancer Module, *QoL* quality of life

Primary Endpoint: Progression-Free Survival {#Sec11}
-------------------------------------------

First-line afatinib significantly prolonged median PFS versus chemotherapy in both LL3 (11.1 vs. 6.9 months; hazard ratio \[HR\] 0.58 \[95 % confidence interval (CI) 0.43--0.78; *p* = 0.001\]) and LL6 (11.0 vs. 5.6 months; HR 0.28 \[95 % CI 0.20--0.39; p = 0.0001\]; Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}a/b) \[[@CR66], [@CR67]\]. Furthermore, subgroup analyses showed that the PFS benefit was apparent across most clinically relevant subgroups (age, sex, race, Eastern Cooperative Oncology Group \[ECOG\] performance status). When the analysis was restricted to patients with common *EGFR* mutations only, the PFS advantage over chemotherapy was more pronounced. The PFS benefit versus chemotherapy conferred by afatinib, gefitinib, and erlotinib in phase III trials is summarized in Table [1](#Tab1){ref-type="table"}. In the context of previous studies with erlotinib and gefitinib, the median PFS values of 13.6 and 11.0 months achieved with afatinib appear favorable. However, a number of recent meta-analyses have failed to detect any significant differences in efficacy between afatinib and first-generation TKIs \[[@CR71]--[@CR73]\], emphasizing the need for head-to-head data. Nevertheless, a recently published network meta-analysis showed an estimated probability of being best for afatinib over all other treatments for PFS of 70 versus 27 % for erlotinib and 3 % for gefitinib \[[@CR74]\].Fig. 2Progression-free survival for afatinib versus chemotherapy in **a** Lux-Lung 3 \[[@CR66]\] and **b** Lux-Lung 6 \[[@CR67]\]. **a** Sequist, LV et al: J Clin Oncol 31 (27), 2013: 3327--34. Reprinted with permission. © (2013) American Society of Clinical Oncology. All rights reserved. **b** Reprinted from The Lancet Oncology, Vol. 15, Wu YL et al, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, pp. 213--22, 2014, with permission from Elsevier. *CI* confidence interval, *Cis/Gem* cisplatin/gemcitabine, *Cis/Pem* cisplatin/pemetrexed, *PFS* progression-free survival

Interestingly, afatinib also appears to be active in a subset of patients with certain uncommon *EGFR* mutations. In a pooled analysis of LL3, LL6, and the phase II LL2 study \[[@CR75]\], patients with rare mutations/duplications in exons 18--21 (*n* = 38) who received afatinib had a median PFS of 10.7 months \[[@CR76]\]. However, for 14 patients with de novo *T790M* mutations, outcomes were variable but generally poor. In these patients, the response rate was 14.3 %, median PFS was 2.9 months, and OS was 14.9 months \[[@CR76]\]. Given the small sample size, these data should be interpreted with caution. However, it may be that chemotherapy may be the most appropriate treatment option in patients with de novo *T790M* mutations. Nevertheless, given that afatinib shows preclinical activity against *T790M* in vitro and in vivo, further studies are warranted in patients with *T790M*-positive tumors. One ongoing study, for example, is examining the feasibility of intermittent high-dose afatinib in such patients (NCT01647711). In LL3, LL6, and LL2, outcomes were also poor against tumors harboring exon 20 insertions (median PFS 2.7 months, *n* = 23).

Another sub-analysis (of the LL3 study) indicated that afatinib is also beneficial in patients with brain metastases \[[@CR77]\]. In this subgroup (*n* = 35), median PFS with afatinib versus chemotherapy was 11.1 vs. 5.4 months (HR 0.52 \[95 % CI 0.22--1.23; *p* = 0.13\]). Among patients with intracranial progression (*n* = 10), median time to progression was 11.6 months with afatinib versus 5.5 months with chemotherapy \[[@CR77]\]. Furthermore, a compassionate use program indicated that afatinib had clinical activity in NSCLC patients with central nervous system metastases who had progressed on chemotherapy and an EGFR-TKI \[[@CR78]\]. Further analyses of afatinib in NSCLC patients harboring uncommon *EGFR* mutations or with brain metastases are ongoing.

Key Secondary Endpoint: Overall Survival {#Sec12}
----------------------------------------

Median follow-up for OS was 41 and 33 months in LL3 and LL6, respectively \[[@CR68]\]. In the overall dataset (all *EGFR* mutations), no significant difference in median OS was observed between the afatinib and chemotherapy arms (LL3 28.2 vs. 28.2 months; HR 0.88 \[95 % CI 0.66--1.17; *p* = 0.39\]; LL6 23.1 vs. 23.5 months; HR 0.93 \[95 % CI 0.72--1.22; *p* = 0.61\]). Interestingly, in a prespecified analysis, median OS was significantly improved with afatinib compared with chemotherapy in patients harboring *Del19* mutations in both LL3 (33.3 vs. 21.1 months; HR 0.54 \[95 % CI 0.36--0.79; *p* = 0.0015\]) and LL6 (31.4 vs. 18.4 months; HR 0.64 \[95 % CI 0.44--0.94; *p* = 0.0229\]; Table [1](#Tab1){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}a/b); no OS difference was observed in the *L858R* mutation-positive subgroup. However, in a prespecified analysis of median OS in patients with common mutations (*Del19/L858R*), a trend towards OS benefit was observed (LL3 31.6 vs. 28.2 months; HR 0.78 \[95 % CI 0.58--1.06; p = 0.11\]; LL6 23.6 vs. 23.5 months; HR 0.83 \[95 % CI 0.62--1.09; *p* = 0.18\]; Table [1](#Tab1){ref-type="table"}). Afatinib is the first agent to demonstrate improved OS versus standard-of-care platinum-doublet chemotherapy in a molecularly-defined population of patients with NSCLC. No head-to-head studies are currently available to allow direct comparison of OS achieved with afatinib versus first-generation EGFR-TKIs. However, a phase IIb trial comparing first-line afatinib versus gefitinib with *EGFR* mutation-positive lung adenocarcinoma is ongoing (NCT01466660).Fig. 3Overall survival in patients with exon 19 deletions in LUX-Lung 3 and LUX-Lung 6 \[[@CR68]\]. Reprinted from The Lancet Oncology, Vol. 16, Yang JC et al, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, pp. 141--51, 2015, with permission from Elsevier. *CI* confidence interval, *Cis/Gem* cisplatin/gemcitabine, *Cis/Pem* cisplatin/pemetrexed, *OS* overall survival

While the majority of patients in LL3, and all patients in LL6, were Asian, the OS benefit with afatinib over chemotherapy in patients harboring the *EGFRDel19* mutation was independent of ethnicity; OS in non-Asian patients (*n* = 46) was 33.6 vs. 20.0 months (HR 0.45 \[95 % CI 0.21--0.95; *p* = 0.03\]) \[[@CR68]\]; OS in Asian patients (LL3 and LL6 combined; *n* = 309) was 31.7 vs. 21.1 months (HR 0.61 \[95 % CI 0.46--0.82; *p* \< 0.01\]) \[[@CR79]\]. Furthermore, a significant OS improvement with afatinib versus chemotherapy in patients harboring the *Del19* mutation was observed in the Chinese subgroup of LL6 (*n* = 166; 31.6 vs. 16.3 months; HR 0.61 \[95 % CI 0.41--0.91; *p* = 0.015\]) and in the Japanese subgroup of LL3 (*n* = 39; 46.9 vs. 31.5 months; HR 0.34 \[95 % CI 0.13--0.87; *p* = 0.018\]) \[[@CR80], [@CR81]\]. The more pronounced OS benefit observed with afatinib in Japanese patients may reflect greater access to subsequent therapies following disease progression \[[@CR68]\]. These subgroup data support the applicability of the OS findings in LL3 and LL6 to all patients with *EGFR* mutation-positive disease, regardless of race/ethnicity.

In contrast to afatinib, neither erlotinib nor gefitinib demonstrated an OS benefit versus chemotherapy in patients harboring *Del19* or, indeed, *L858R* mutation-positive disease \[[@CR21], [@CR26], [@CR28]\]. The lack of OS benefit with gefitinib or erlotinib versus chemotherapy, either in total datasets or in patients with the *EGFR Del19* mutation (Table [1](#Tab1){ref-type="table"}) \[[@CR17], [@CR25]--[@CR30]\], has been attributed, at least partially, to post-progression therapy with EGFR-TKIs in patients initially randomized to chemotherapy \[[@CR17], [@CR25]--[@CR27], [@CR29], [@CR30]\]. In this context, it is interesting to note that crossover rates in LL3 and LL6 were similar to those in phase III trials with gefitinib or erlotinib in this setting \[[@CR21], [@CR23], [@CR25]--[@CR27]\]. Furthermore, in LL3, a significant OS benefit with afatinib versus chemotherapy was observed in Japanese patients despite the fact that nearly all chemotherapy-treated patients in this sub-analysis received an EGFR-TKI following disease progression \[[@CR80]\].

Taken together, OS analyses in LL3 and LL6 indicate that afatinib should be considered as a first-line therapy for patients with *EGFR Del19* mutation-positive lung adenocarcinoma \[[@CR82]\], and is also a valuable option for patients with *EGFR* mutation-positive NSCLC harboring other common mutations (*L858R*) as well as a subset of patients with certain uncommon mutations. The significantly and substantially longer OS achieved by afatinib in *Del19* patients further suggests that patients with *EGFR Del19* and *L858R* mutation-positive disease should be studied separately in future trials evaluating TKIs in patients with *EGFR* mutation-positive NSCLC.

Patient-Reported Outcomes {#Sec13}
-------------------------

Disease-related symptoms, treatment-related adverse events (AEs), and treatment efficacy all substantially influence patients' QoL \[[@CR83]\]. In order to assess the effect of afatinib on QoL, both LL3 and LL6 fully integrated comprehensive PRO evaluation into outcome analyses (Table [3](#Tab3){ref-type="table"}). In contrast with IPASS (which utilized Functional Assessment of Cancer Therapy indices) and EURTAC (where insufficient PRO data were collected for analysis), the afatinib trials assessed both EORTC QLQ-LC13 and QLQ-C30. This provided a complete picture of both lung cancer-related symptoms and symptoms related to treatment. These analyses demonstrated that afatinib improved prespecified lung cancer-related symptoms (cough, dyspnea, and pain) and delayed their deterioration versus chemotherapy. In LL3, afatinib significantly delayed time to deterioration for cough (*p* = 0.007) and dyspnea (*p* = 0.015), but not pain (*p* = 0.19), and was associated with improved mean scores over time for cough and dyspnea (both *p* \< 0.001). Improvements in mean scores over time were also observed with afatinib versus chemotherapy for functional health status/QoL (*p* = 0.015) and physical (*p* \< 0.001), role (*p* = 0.004), and cognitive (*p* = 0.007) functioning \[[@CR66], [@CR70]\]. In LL6, afatinib significantly delayed time to deterioration for cough (*p* \< 0.0001), dyspnea (*p* \< 0.0001), and pain (*p* = 0.027) versus chemotherapy, and was associated with improvements in mean scores over time for each symptom (all *p* \< 0.0001). Furthermore, more patients treated with afatinib versus chemotherapy showed longer time to deterioration (*p* = 0.0002), better mean scores over time (*p* \< 0.0001), and improvements from baseline in global health status/QoL (*p* \< 0.0001) \[[@CR67]\].

Safety/Tolerability {#Sec14}
-------------------

In both LL3 and LL6, afatinib was associated with predictable and manageable AE profiles, and low discontinuation rates due to treatment-related AEs. In LL3, grade 3 or higher treatment-related AEs occurred in 112 (49 %) patients receiving afatinib and 53 (48 %) patients receiving chemotherapy \[[@CR66]\]. The most common treatment-related AEs (all grades/grade 3 or higher) were diarrhea (95/14 %) rash/acne (89/16 %), stomatitis/mucositis (72/9 %), and paronychia (57/11 %) in the afatinib arm and nausea (66/4 %), decreased appetite (53/3 %), fatigue (47/13 %), and vomiting (42/3 %) in the chemotherapy arm. Therapy was discontinued because of treatment-related AEs in 8 % of those receiving afatinib and 12 % of those receiving chemotherapy. Of the most common AEs associated with afatinib, only diarrhea (1.3 %) and paronychia (0.9 %) resulted in treatment discontinuation. In LL6, treatment-related AEs grade 3 or higher occurred in 86 (36 %) patients receiving afatinib and 68 (60 %) patients receiving chemotherapy \[[@CR67]\]. As with LL3, the most common treatment-related AEs (all grades/grade 3 or higher) were diarrhea (88/5 %), rash/acne (81/15 %), stomatitis/mucositis (52/5 %), and paronychia (33/0 %) in the afatinib arm and vomiting (81/19 %), nausea (75/8 %), decreased appetite (41/2 %), and fatigue (36/1 %) in the chemotherapy arm. Therapy was discontinued because of treatment-related AEs in 6 % of patients receiving afatinib and 40 % of patients receiving chemotherapy. The most common cause of discontinuation in the afatinib arm was rash/acne (2 %). No patients discontinued due to diarrhea only.

Adverse Event Management {#Sec15}
------------------------

In general, drug-related AEs were effectively managed with supportive care and/or protocol-defined dose reductions and led to few treatment-related discontinuations \[[@CR66], [@CR67]\]. Of note, afatinib-treated patients were permitted to dose-escalate from the initial 40 mg dose to 50 mg/day after the first 21-day treatment cycle if no drug-related AEs higher than grade 1 were experienced, while dose reductions in 10 mg decrements to a minimum final dose of 20 mg were recommended for patients experiencing drug-related grade 3 or selected prolonged grade 2 AEs \[[@CR66], [@CR67]\]. This active management of AEs associated with afatinib facilitates treatment compliance and improvements in PROs, and allows patients to achieve maximum therapeutic benefit with this agent \[[@CR84], [@CR85]\].

In LL3, pharmacokinetic assessments demonstrated similar geometric mean plasma concentrations of afatinib for all permitted dose groups (20, 30, 40, and 50 mg) after tolerability-guided dose adjustments \[[@CR66]\]. Importantly, protocol-defined dose reductions based on individual patient AEs were shown to reduce excessive plasma concentrations of afatinib, thereby optimizing patient exposure to the active drug as well as managing tolerability without compromising efficacy \[[@CR66]\].

Summary {#Sec16}
-------

In two large phase III trials, afatinib demonstrated OS benefit versus chemotherapy in patients harboring *Del19* mutations, the most common *EGFR* aberration in patients with NSCLC. Based on these observations, some commentators have concluded that afatinib should be considered as a first-line therapy for patients with *EGFR Del19* mutation-positive lung adenocarcinoma \[[@CR68], [@CR82]\]. Although no significant difference in OS was observed in patients harboring the *L858R* mutation, significant improvements over chemotherapy in PFS and PROs of disease-related symptoms and QoL, as well as a predictable and manageable safety profile in all patients with *EGFR* mutation-positive NSCLC, including the *L858R* mutation, suggest an important clinical benefit with afatinib in patients with *EGFR* mutation-positive disease \[[@CR66]--[@CR68]\].

Clinical Trials of Afatinib in the Relapsed/Refractory Setting in Patients with NSCLC {#Sec17}
=====================================================================================

LUX-Lung 1 (LL1) {#Sec18}
----------------

In this phase IIb/III trial, afatinib monotherapy (50 mg/day) was evaluated versus placebo in patients (*n* = 585) with stage IIIb or IV lung adenocarcinoma following failure of up to two lines of chemotherapy and ≥12 weeks of erlotinib and/or gefitinib \[[@CR86], [@CR87]\]. The primary endpoint was OS; secondary endpoints included PFS and OR; health-related QoL was also assessed.

A positive test for *EGFR* mutation status was not required for enrollment; however, the *EGFR* mutation status of 141 patients was known, and 68 % of these patients had activating *EGFR* mutations. Clinical endpoints were assessed in a subpopulation of patients who were clinically enriched for *EGFR* mutations based on Jackman criteria \[[@CR88]\], i.e. patients with a known EGFR-activating mutation plus patients who had achieved an OR or durable stable disease (SD) for \>6 months, followed by systemic disease progression of disease, on continuous gefitinib/erlotinib treatment.

A significant improvement in median PFS was observed with afatinib over placebo (3.3 vs. 1.1 months; HR 0.38 \[95 % CI 0.31--0.48; *p* \< 0.0001\]) \[[@CR86]\]. In a subgroup analysis of patients who met Jackman criteria of acquired resistance (*n* = 214), median PFS was 4.5 versus 1.0 months in the afatinib and placebo arms, respectively (HR 0.37 \[95 % CI 0.26--0.52\]). The prolongation of PFS observed with afatinib was associated with improvements in lung cancer-related symptoms, with a significantly higher proportion of patients having improvements in disease-related cough (*p* \< 0.0001), dyspnea (*p* = 0.006), and pain (*p* \< 0.0001) \[[@CR87]\]. Improvements in EORTC global health status, physical functioning, and fatigue were also observed with afatinib (all *p* \< 0.05).

Median OS was not significantly different with afatinib versus placebo (10.8 vs. 12.0 months; HR 1.08 \[95 % CI 0.86--1.35; *p* = 0.74\]). However, of note, more patients in the placebo group (79 %) than in the afatinib group (68 %) received subsequent anticancer therapies following discontinuation of study medication, including EGFR-TKIs, which potentially confounded the OS results. No complete responses (CRs) were noted in either arm; partial responses (PRs) were observed in 29 (7 %) patients in the afatinib group and one (\<1 %) patient in the placebo group. Afatinib was associated with a manageable safety profile. Diarrhea (17 %) and rash/acne (14 %) were the most common grade 3 AEs; however, these events led to few treatment discontinuations (3.6 and 1.8 %, respectively) \[[@CR86]\].

Although no OS benefit was observed with afatinib over placebo in LL1, improvements in PFS, tumor response, and PROs of disease-related symptoms with afatinib suggested that this agent could potentially be of benefit to patients with advanced NSCLC who had failed previous EGFR-TKI therapy.

LUX-Lung 5 (LL5) {#Sec19}
----------------

The phase III LL5 trial evaluated the efficacy and safety of continued irreversible ErbB family blockade with afatinib combined with paclitaxel versus investigator's choice of chemotherapy alone in patients with NSCLC who had acquired resistance to prior erlotinib/gefitinib and afatinib monotherapy \[[@CR89]\]. The study was conducted over two stages.

In part A, patients who had failed one or more line of chemotherapy and erlotinib/gefitinib (after ≥12 weeks of treatment) were treated with afatinib monotherapy (50 mg/day). In part B, patients achieving ≥12 weeks of benefit (CR/PR/SD) with afatinib monotherapy (*n* = 202) were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m^2^/week) or physician's choice of single-agent chemotherapy. The primary endpoint was PFS; other endpoints included objective response rate (ORR), OS, safety, and PROs.

Significant improvements in median PFS (5.6 vs. 2.8 months; HR 0.60 \[95 % CI 0.43--0.85; *p* = 0.003\]) and ORR (32.1 vs. 13.2 %; HR 3.41 \[95 % CI 1.41--6.79; *p* = 0.005\]) were observed with afatinib plus paclitaxel compared with chemotherapy alone \[[@CR89]\]. However, there was no significant difference in OS (12.2 vs. 12.2 months; HR 1.00 \[95 % CI 0.70--1.43; *p* = 0.994\]); this could reflect differences in post-progression treatment between arms. Patients had received at least four lines of therapy at randomization to afatinib plus paclitaxel or chemotherapy, and approximately 60 % of patients received at least one subsequent therapy post-progression. More patients in the chemotherapy arm received two additional lines of therapy than in the afatinib plus paclitaxel arm (36 vs. 15 %).

There was a trend towards delayed time to deterioration of dyspnea (3.1 vs. 1.8 months; HR 0.78 \[95 % CI 0.55--1.09; *p* = 0.144\]) and pain (4.3 vs. 3.5 months; HR 0.80 \[95 % CI 0.56--1.14; *p* = 0.212\]) but not cough (5.7 vs. 6.5 months; HR 1.13 \[95 % CI 0.79--1.62; *p* = 0.505\]) in patients receiving paclitaxel versus chemotherapy \[[@CR90]\]. There was also a trend towards an increased proportion of patients with improvements in dyspnea (45 vs. 35 %; *p* = 0.222) and cough (46 vs. 36 %; *p* = 0.225) in patients receiving afatinib plus paclitaxel; differences in mean scores over time also favored afatinib plus paclitaxel for dyspnea (−2.9; *p* = 0.191) and cough (−3.8; *p* = 0.201). Afatinib plus paclitaxel had a manageable AE profile; treatment-related AEs were consistent with those previously reported for each agent, with (all grades) diarrhea (53.8 vs. 6.7 %), alopecia (32.6 vs. 15.0 %), and asthenia (27.3 vs. 28.3 %) as the most common treatment-related AEs observed with afatinib plus paclitaxel versus chemotherapy \[[@CR89]\]. This manageable AE profile and QoL maintenance was observed despite the prolonged exposure to afatinib plus paclitaxel (median 133 days) compared with chemotherapy (median 51 days).

In summary, LL5 is the first randomized trial to demonstrate prospective evidence/proof of concept for maintaining irreversible ErbB family inhibition beyond disease progression in oncogene-addicted lung cancer. Overall, these findings support the hypothesis that tumors progressing on erlotinib/gefitinib and afatinib continue to depend on ErbB family receptor signaling and can benefit from continuous ErbB family blockade with afatinib. Interestingly, it was recently reported that gefitinib post-progression (combined with cisplatin + pemetrexed) did not confer any clinical benefit versus chemotherapy alone in patients with confirmed activating *EGFR* mutations progressing after first-line gefitinib monotherapy \[[@CR91]\].

Afatinib in Combination Regimens {#Sec20}
================================

Rationale {#Sec21}
---------

The pharmacokinetic properties of afatinib are conducive to the development of novel combination regimens with other drugs. Afatinib is an orally bioavailable agent that achieves peak plasma concentrations \~2--5 h after dosing \[[@CR92], [@CR93]\]. Due to its high solubility (pH range 1.0--7.5), interactions with acid-reducing drugs are not expected. Unlike the reversible EGFR-TKIs erlotinib and gefitinib, oxidative and cytochrome P450 (CYP) enzyme-dependent metabolism are of negligible importance for afatinib; thus, the potential for interaction with other agents that are either metabolized by, or are inhibitors or inducers of, CYP-related enzymes, is low \[[@CR92], [@CR94]\]. This overall low probability of drug--drug interactions makes afatinib an attractive combination partner for chemotherapies and other targeted therapies. In this context, a substantial number of clinical studies aimed to identify potential combination partners and patients who may benefit from particular combination therapies have been undertaken or are ongoing (e.g. NCT01999985, NCT02191891, NCT01861223) \[[@CR95]--[@CR103]\].

Dual Inhibition of EGFR with Afatinib and Cetuximab in TKI-Resistant *EGFR*-Mutant Lung Cancer with and without *T790M* Mutations {#Sec22}
---------------------------------------------------------------------------------------------------------------------------------

In a recent phase Ib study, afatinib combined with the anti-EGFR monoclonal antibody, cetuximab, has demonstrated promising activity in patients who had failed on erlotinib or gefitinib \[[@CR104]\]. In 126 patients treated with the MTD of afatinib plus cetuximab, the confirmed OR rate was 29 %; interestingly, the response rate was similar in patients harboring *T790M*-positive and *T790M*-negative tumors (32 vs. 25 %; *p* = 0.341). The mode of action for the observed clinical efficacy is currently unknown. It could be related to the fact that the tumor cells remain dependent on ErbB signaling (due to acquired *EGFR* mutations, EGFR amplification, and/or HER2 amplification); as such, simultaneous vertical inhibition of the intracellular domain of the ErbB receptors with afatinib and the extracellular domain of EGFR with cetuximab might result in increased efficacy compared with monotherapy with either agent \[[@CR104]\].

These preliminary data are encouraging given that no approved treatment options are currently available for patients with acquired resistance to first-generation inhibitors. In this context, findings from phase I dose-escalation trials of third-generation EGFR inhibitors (designed to bind with higher affinity to EGFR harboring *T790M*), including AZD-9291, CO-1686, and HM-61713, are also promising. These studies reported \>50 % response rates in patients with *EGFRT790M*-positive NSCLC who had failed previous first-generation EGFR-TKI therapy \[[@CR105]--[@CR107]\].

Second-Line Treatment for Patients with Squamous Cell Carcinoma of the Lung: LUX-Lung 8 (LL8) {#Sec23}
=============================================================================================

Squamous histology represents approximately 30 % of NSCLC \[[@CR108]\], and there is a major unmet need for effective treatments in patients with squamous cell carcinoma (SCC) of the lung. Targetable oncogenic alterations are limited and have not yet translated to a therapeutic paradigm. Despite the fact that *EGFR* mutations are rare in tumors with squamous cell histology (\<5 %) \[[@CR109]\], afatinib has shown encouraging activity in such tumor types, including a subset of patients with SCC in LL5 \[[@CR110]\] and SCC of the head and neck \[[@CR111]\]. This may reflect the observation that SCCs often overexpress EGFR \[[@CR112]--[@CR114]\]. Furthermore, other ErbB receptors or their cognate ligands have been shown to be overexpressed, amplified, or mutated in patients with SCC of the lung \[[@CR115]--[@CR117]\].

LL8 is the first phase III trial to prospectively compare second-line EGFR-TKIs in patients with SCC of the lung \[[@CR118]\]. In this global study, patients (*n* = 795) with relapsed/refractory stage IIIb/IV SCC were randomized 1:1 to receive afatinib (40 mg/day) or erlotinib (150 mg/day). Patients recruited to this trial had progressed after four or more cycles of platinum-based doublet chemotherapy and had not received prior EGFR-TKI therapy. The primary endpoint was PFS as assessed by independent radiological review (IRR). Secondary endpoints included OS, ORR, disease control rate (DCR), PROs, and safety. A significant improvement in median PFS was observed with afatinib versus erlotinib (2.6 vs. 1.9 months; HR 0.81 \[95 % CI 0.69--0.96; *p* = 0.010\]) \[[@CR118]\]. Notably, given the paucity of second-line treatment options in patients with SCC of the lung, afatinib significantly improved OS versus erlotinib (7.9 vs. 6.8 months; HR 0.81 \[95 % CI 0.69--0.95; *p* = 0.008\]) \[[@CR118]\]. DCR was significantly higher with afatinib versus erlotinib (50.5 vs. 39.5 %; *p* = 0.002); ORR was 5.5 % with afatinib and 2.8 % with erlotinib (*p* = 0.055).

The overall AE profile for afatinib and erlotinib was comparable, with grade 3 or higher AEs reported in 57.1 and 57.5 % of patients, respectively. A higher incidence of drug-related grade 3 or higher diarrhea (10.4 vs. 2.6 %) and grade 3 stomatitis (4.1 vs. 0.0 %) was observed with afatinib, and a higher incidence of grade 3 rash/acne was observed with erlotinib (5.9 vs. 10.4 %) \[[@CR118]\]. Furthermore, more patients in the afatinib arm reported improved global health status/QoL (35.7 vs. 28.3 %; *p* = 0.041) and cough (43.4 vs. 35.2 %; *p* = 0.029) versus erlotinib. Taken together, these findings indicate that afatinib provides a significant improvement in PFS, OS, and DCR versus erlotinib, with a predictable and manageable AE profile, consistent with the mechanistic profile of EGFR inhibition, in patients with relapsed/refractory SCC.

Conclusions {#Sec24}
===========

In patients with advanced *EGFR* mutation-positive NSCLC, first-line afatinib significantly improved PFS, PROs, and QoL versus standard-of-care platinum-doublet chemotherapy regimens in two large phase III studies. In addition, afatinib demonstrated a significant OS advantage versus chemotherapy in patients with NSCLC harboring *EGFRDel19* mutations. These findings suggest that afatinib could be considered the preferred first-line treatment option for NSCLC patients with *EGFRDel19* mutations, although head-to-head data will be helpful to confirm this assertion. Furthermore, the improvements in PFS and PROs observed with afatinib regardless of mutation type indicate that important clinical benefits are achieved with afatinib in all patients with common *EGFR* mutation-positive NSCLC. Afatinib has also demonstrated promising activity in patients who have failed on erlotinib and gefitinib and in patients with active brain metastases. In patients with SCC of the lung who have failed on first-line chemotherapy, afatinib significantly improved PFS, OS, and DCR versus erlotinib. Several clinical studies are currently ongoing that will help further define the role of afatinib in a relapsed/refractory setting.
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